Providing options.
Delivering hope.

We are a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.

Our third-generation cellular analysis platform unravels complex oncogenic activity molecular tests can’t detect.

See our approach

Our discoveries create new potential applications for targeted therapies.

View our pipeline

Our comparative analyses of different drugs use live patient tumor cells, revealing opportunities to develop first-in-class drugs.

Learn about Gedatolisib

News

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Celcuity Presents OS Data from Phase 1b Study Evaluating Gedatolisib with Palbociclib and Letrozole at the 2024 SABCS

See all news